This review concluded that chemoprophylaxis was effective in lowering the incidence of leprosy in contacts of patients diagnosed with the disease. This was a well-conducted review and despite the small number of trials of limited quality the findings reflected the evidence presented and are likely to be reliable. The generalisability of the findings to less endemic populations was unclear.
Study selection
Randomised controlled trials (RCTs) that compared chemoprophylaxis of contacts of patients with leprosy against no intervention, placebo or other chemoprophylaxis schemes were eligible for inclusion; studies where the intervention group included vaccines were excluded. The main outcome was diagnosis of leprosy (secondary cases) in contacts of patients with the disease (primary cases).
All of the included studies were conducted in highly endemic populations in Asia (mostly India) and included both adults and children. Treatments, at varying doses and durations, included acedapsone, dapsone, rifampicin, ofloxacine and minocycline; the comparator for all studies was placebo. Most studies applied clinical criteria for leprosy diagnosis; positive bacilloscopy in slit skin smears was also used. Most RCTs included close contacts of leprosy patients or both household and community contacts. The type of disease in the primary case (paucibacillary and multibacillary leprosy) was reported in less than a third of studies.
Two independent reviewers selected studies for inclusion in the review; disagreements were resolved by referral to a third author.
Assessment of study quality
Study quality was assessed according to the criteria: sequence generation; allocation concealment; blinding; incomplete outcome data; selective outcome reporting; and other sources of bias. An overall assessment categorised studies as either a low or high risk of bias.
The authors did not state how many reviewers performed the quality assessment.
Data extraction
Two reviewers independently extracted relevant data to derive relative risk (RR) for dichotomous outcomes and mean differences for continuous outcomes; disagreements were resolved by consensus of all authors. Authors were contacted for additional data. Pooled relative risks and weighted mean differences (WMD) and their 95% confidence intervals (CI) were calculated using a random-effects model (Mantel-Haenszel) . Heterogeneity was assessed using the I 2 tests (high levels of heterogeneity were defined as I 2 >70%). Analyses were based on intention-to-treat. Subgroup analyses were undertaken to assess the impact of: specific drugs, diagnostic criteria, gender proportions, age, geographic areas, drug dosages and study quality. Numbers needed to treat (NNT) to prevent one case of leprosy were calculated.
Methods of synthesis

Results of the review
Seven RCTs (n=66,311) were included in the review. One RCT had a low risk of bias. Generation and concealment of sequence were reported adequately in two studies. Staff and participant blinding was reported in four studies. Duration of follow-up ranged from least two years to 8.5 years.
Chemoprophylaxis was significantly better than placebo for prevention of secondary cases of leprosy at two and four years of follow-up (RR 0.59, 95% CI 0.50 to 0.70; six studies). Compared with placebo, single-dose rifampicin (RR 0.43, 95% CI 0.28 to 0.67; one study, NNT 285), dapsone once or twice weekly for at least two years (RR 0.60, 95% CI 0.48 to 0.76; three studies) and acedapsone every 10 weeks for seven months (RR 0.49, 95% CI 0.33 to 0.72; two studies) were significantly superior in prevention of secondary cases of leprosy. Heterogeneity was absent from all comparisons.
